Physician profile
Thomas Greenwell
NPI 1013913474
$98,088.59
in general payments reported to CMS, 2019-2025
32 companies · $3,150 in 2025
The $3,150 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,502 · 2021: $29K · 2022: $29K · 2023: $17K · 2024: $1,468 · 2025: $3,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,227.26 |
| Food and Beverage | $727.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $70,619.73 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $23,970.42 | 2019-2021 | |
| Abbvie INC. | $1,015.06 | 2019-2023 | |
| Amgen INC. | $416.14 | 2019-2023 | Prolia |
| Mayne Pharma Commercial LLC | $326.86 | 2022-2023 | |
| Hologic Sales and Service, LLC | $221.00 | 2019-2024 | Aptima |
| Myovant Sciences INC. | $203.24 | 2021-2022 | |
| Daiichi Sankyo INC. | $168.91 | 2019-2022 | |
| Boston Scientific Corporation | $137.45 | 2019-2022 | |
| Novo Nordisk INC | $132.39 | 2020-2023 | Wegovy |
| Astellas Pharma US INC | $118.86 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $114.06 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.81 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $59.91 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $53.73 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $46.48 | 2022 | |
| Therapeuticsmd, INC. | $39.90 | 2020-2022 | |
| Allergan, INC. | $36.49 | 2019-2020 | |
| Avion Pharmaceuticals | $34.87 | 2021 | |
| Coopersurgical, INC. | $33.64 | 2019-2023 | Paragard T 380a |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.01 | 2020 | |
| Pfizer INC. | $29.30 | 2022-2023 | |
| Agile Therapeutics, INC. | $28.03 | 2022 | |
| Evofem Biosciences, INC. | $27.58 | 2021-2022 | |
| Convatec INC. | $24.97 | 2022 | |
| Channel Medsystems, INC. | $18.80 | 2022 | |
| Becton, Dickinson and Company | $17.71 | 2021 | |
| Minerva Surgical, INC | $14.40 | 2021 | |
| Medtronic, INC. | $14.20 | 2023 | Truclear |
| Bausch Health US, LLC | $13.86 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.93 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Greenwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.